Long-term clinical outcomes of differentiated thyroid cancer patients with biochemical incomplete response after initial radioiodine therapy, a single-center, retrospective analysis

Key Points

• Biochemical incomplete response indicates potential progression in patients with thyroid cancer.
• Key metrics are sTg levels higher than 50.0 ng/mL and T3b-T4 stages, pointing towards disease progression.
• Clinical markers were identified through a retrospective analysis of patient outcomes from initial treatments.
• These findings highlight the need for intensified monitoring and possible re-evaluation of therapeutic strategies.